Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
Authors:
Top Cited Papers
- 1 November 2007
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (11) , 2178-2185
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysisBritish Journal of Clinical Pharmacology, 2006
- Oral Anticoagulants in DevelopmentDrugs, 2006
- Emerging anticoagulants for the treatment of venous thromboembolismThrombosis and Haemostasis, 2006
- Antithrombotic Therapy Practices in US Hospitals in an Era of Practice GuidelinesArchives of internal medicine (1960), 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trialsActa Radiologica, 1997
- On closed testing procedures with special reference to ordered analysis of varianceBiometrika, 1976
- On Closed Testing Procedures with Special Reference to Ordered Analysis of VarianceBiometrika, 1976
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972